CLINICAL TRIALS PROFILE FOR MDP-BRACCO

All Clinical Trials for Mdp-bracco

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00590070 ↗	THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction	Completed	Catholic University of the Sacred Heart	Phase 2/Phase 3	2008-01-01	The occurrence of no-reflow phenomenon after recanalization of the infarct related artery in acute myocardial infarction is described in up to 40% of cases. This event is associated with a worse prognosis at follow up and an unfavourable left ventricular remodelling . Two main pathogenetic mechanisms cause no-reflow: distal embolization and ischemia-reperfusion injury. Due to the multifactorial pathogenesis of no-reflow during acute MI a combined mechanic and pharmacologic approach is believed to offer a better solution for achieving optimal microvascular reperfusion. Thus, in this randomized study we will assess the effect of nitroprusside or adenosine in adjunct to current best therapy (thrombus aspiration and IIb-IIIa antagonists) for ST elevation MI using ST segment resolution on standard 12 leads ECG as primary endpoint of myocardial reperfusion.
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Johns Hopkins University	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Memorial Health University Medical Center	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Penn State University	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Temple University	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.
NCT01481441 ↗	Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer	Terminated	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	N/A	2011-11-01	With Contrast Enhanced UltraSound (CEUS) cancer induced neovascularisation can be visualised with the potential to improve ultrasound imaging for prostate cancer detection and localisation significantly. The past years numerous studies have been performed with CEUS, all basing their results on subjective judgement of the investigator. CEUS image interpretation is difficult and requires a well-trained expert. To overcome these difficulties CEUS quantification techniques can be of use. The techniques used in this protocol have been developed in cooperation with the Technical University in Eindhoven (TU/e) and BRACCO, Geneva. The investigators hypothesize improvement of the PCa detection rate with quantification, compared with subjective CEUS interpretation and known numbers in literature. Also a comparison between quantification results and tumour differentiation grade (Gleason score) will be made, the investigators hypothesize a positive correlation.
NCT02502747 ↗	RIGENERA 2.0 Trial	Suspended	Catholic University of the Sacred Heart	Phase 2	2020-01-01	Study Objectives: To determine whether, in patients with large acute myocardial infarction undergoing primary or rescue angioplasty, the administration of subcutaneous Lenograstim [recombinant human Granulocyte-Colony Stimulating Factor (rhu G-CSF), Myelostim 34, Italfarmaco] associated with Myocardial Contrast Echocardiography and the intravenous infusion of sulphur hexafluoride (Sonovue, Bracco) determines an improvement: - in regional and global contractile function, myocardial perfusion and infarct size assessed by cardiovascular magnetic resonance. - Echocardiographic parameters of LV function - in the serum profile of inflammatory and mobilizing cytokines and of biomarkers of myocardial damage and wall stress

Clinical Trial Conditions for Mdp-bracco

Condition Name

Condition Name for Mdp-bracco
Intervention	Trials
Motor Function	1
Cognitive Function	1
Myocardial Infarction	1
Contrast Media	1

Condition MeSH

Condition MeSH for Mdp-bracco
Intervention	Trials
Myocardial Infarction	3
Infarction	3
Stroke	1
Hypoxia	1

Clinical Trial Locations for Mdp-bracco

Trials by Country

Trials by Country for Mdp-bracco
Location	Trials
United States	10
Italy	2
Netherlands	1
Belgium	1
Germany	1

Trials by US State

Trials by US State for Mdp-bracco
Location	Trials
Pennsylvania	4
North Carolina	1
Massachusetts	1
Illinois	1
Arizona	1

Clinical Trial Progress for Mdp-bracco

Clinical Trial Phase

Clinical Trial Phase for Mdp-bracco
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	4
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Mdp-bracco
Clinical Trial Phase	Trials
Recruiting	4
Completed	4
Terminated	2

Clinical Trial Sponsors for Mdp-bracco

Sponsor Name

Sponsor Name for Mdp-bracco
Sponsor	Trials
Children's Hospital of Philadelphia	3
Catholic University of the Sacred Heart	2
Bracco Diagnostics, Inc	2

Sponsor Type

Sponsor Type for Mdp-bracco
Sponsor	Trials
Other	22
Industry	4

Last updated: April 24, 2026

Clinical Trials Update, Market Analysis, and Projections for “MDP-Bracco”

No valid, unambiguous drug-identification inputs are present to map “MDP-Bracco” to a specific approved product name, international nonproprietary name (INN), active pharmaceutical ingredient, strength/formulation, and jurisdictional regulatory status. Without that mapping, a complete and accurate clinical-trials update and market projection cannot be produced.

What exactly is “MDP-Bracco” in regulatory and clinical-trial terms?

No reliable identification of the product, active ingredient, or specific branded formulation is provided in the input.

What clinical trials should be listed and updated?

No trials can be enumerated to a defined investigational product, because “MDP-Bracco” is not mapped to:

• a unique INN/chemical entity,
• a specific brand dossier,
• a defined route of administration and strength,
• or a jurisdiction (FDA/EMA/PMDA/other) for eligibility and endpoints.

What market definition and TAM/SAM/SOM should be modeled?

A market projection requires at minimum:

• indication(s) and target patient population,
• current standard of care and competitor set,
• regulatory status (approved vs. investigational),
• product attributes (dose, imaging modality vs therapeutic, dosing frequency, reimbursement access),
• geography and forecast horizon. None of these are specified or determinable from the input.

---

Key Takeaways

• A complete clinical trials update and market projection cannot be generated because “MDP-Bracco” is not mapped to a uniquely identifiable drug product and active ingredient.
• No actionable market-sizing model (TAM/SAM/SOM) can be constructed without indication, regulatory status, and geography.
• No trial list can be compiled without a defined investigational product identity and endpoints.

---

FAQs

1) Can you list completed and ongoing clinical trials for “MDP-Bracco”?
Not without an unambiguous mapping of “MDP-Bracco” to a specific product/active ingredient and regulatory dossier.

2) Can you provide peak sales forecasts and time-to-peak for “MDP-Bracco”?
Not without indication, regulatory status, geography, and competitor benchmarks.

3) Does “MDP-Bracco” refer to a diagnostic or therapeutic product?
The input does not define whether it is diagnostic (imaging tracer) or therapeutic, which is required for market modeling.

4) Which jurisdictions are covered in the clinical and market analysis?
No jurisdictions are specified, and the product identity is not uniquely determined from the input.

5) Can you break down revenue by region and channel (hospital vs outpatient) for “MDP-Bracco”?
Not without a defined product, dosing regimen, and reimbursed setting tied to an identifiable active ingredient and branded product.

---

References

[1] No sources cited because the drug identity cannot be determined from the provided input.